In the United States, they tested a drug for weight loss twice as effective as Ozampi. We are talking about the development of the American pharmaceutical company Eli Lilly. In clinical trials lasting 80 weeks, patients taking retroretide lost an average of 19.5-20.9% of body weight compared to 9.4% in the Ozampica group. The company announced the results of the Phase III study on October 28, ABC News reports. It included 1,298 adult patients with type 2 diabetes. The article also noted that retrotide was more effective in reducing levels of glycated hemoglobin, a measure that reflects the average level of sugar in the blood over several months.

In the United States, they tested a drug for weight loss twice as effective as Ozampi. We are talking about the development of the American pharmaceutical company Eli Lilly. In clinical trials lasting 80 weeks, patients taking retroretide lost an average of 19.5-20.9% of body weight compared to 9.4% in the Ozampica group. The company announced the results of the Phase III study on October 28, ABC News reports. It included 1,298 adult patients with type 2 diabetes. The article also noted that retrotide was more effective in reducing levels of glycated hemoglobin, a measure that reflects the average level of sugar in the blood over several months.